로딩 중…
지수 로딩 중…
우정바이오
215380· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,050+0.24%
2026-11-02
Financials
Valuation Metrics
우정바이오's Market Cap is ₩345B. At end of 2025 it was ₩296B. Ranked #1947 of 2,405 in KR market (top 81%), #1219 of 1,627 on KOSDAQ (top 75%), #207 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 34.50B KRW | KR#1,947/2,405 Sec#207/231 |
| Revenue | 44.20B KRW | KR#1,853/2,405 Sec#130/231 |
| Net Income | 1.24B KRW | KR#1,460/2,405 Sec#100/231 |
| Total Assets | 103.30B KRW | KR#1,749/2,405 Sec#139/231 |
| Net Assets | 26.58B KRW | KR#2,202/2,405 Sec#201/231 |
| Employees | 151 | KR#1,322/2,405 Sec#107/231 |
| Value | ||
| P/E | 27.92x | KR#1,305/2,405 Sec#80/231 |
| P/B | 1.30x | KR#1,730/2,405 Sec#118/231 |
| P/S | 0.78x | KR#1,278/2,405 Sec#70/231 |
| FCF Yield | -2.56% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 4.65% | KR#1,139/2,405 Sec#79/231 |
| ROA | 1.20% | KR#1,371/2,405 Sec#98/231 |
| Op. Margin | -1.08% | KR#1,693/2,405 Sec#114/231 |
| Revenue Growth | 20.78% | KR#531/2,405 Sec#51/231 |
| Financial Health | ||
| Debt Ratio | 288.63% | KR#2,234/2,405 Sec#225/231 |
| Total Debt | 32.98B KRW | KR#1,174/2,405 Sec#85/231 |
| FCF | -884.5M KRW | KR#1,270/2,405 Sec#97/231 |
| Cash | 15.65B KRW | KR#1,399/2,405 Sec#109/231 |
| Current Ratio | 0.55x | KR#2,103/2,405 Sec#202/231 |
| Performance | ||
| 1Y Return | 9.16% | KR#559/2,405 Sec#28/231 |
| 1M Return | -11.64% | KR#1,303/2,405 Sec#127/231 |
| From 52W High | -54.80% | KR#1,386/2,405 Sec#113/231 |
| 1Y MDD | -43.69% | KR#705/2,405 Sec#51/231 |
| Trading | ||
| Volume | 21,908 shares | KR#1,434/2,405 Sec#140/231 |
| Trading Value | 44.4M KRW | KR#1,783/2,405 Sec#190/231 |
| Foreign Own. | 7.71% | KR#576/2,405 Sec#48/231 |
| Per Share | ||
| EPS | 73 KRW | KR#1,471/2,405 Sec#102/231 |
| BPS | 1,579 KRW | KR#2,177/2,405 Sec#188/231 |
Company Info
동사는 1989년 설립되어 2015년 코스닥 상장한 바이오 전문기업으로, 바이오사업과 감염관리사업을 영위함. 바이오사업은 2021년 민간 최초로 구축한 우정바이오 신약클러스터를 통해 비임상CRO서비스와 비바리움 운영사업을 진행하며, 감염관리사업은 과산화수소 증기 멸균법 기반 공간멸균 토탈시스템을 제공함. 축적된 현장경험과 기술력으로 국내 전임상CRO 업계 1위 기업 위상을 구축하고, 글로벌 신약개발 생태계 조성에 주력하고 있음. 우정바이오는 2015년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.